Compass Therapeutics Inc (CMPX) News

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update

Top-line Phase 2/3 data readout for COMPANION-002, evaluating tovecimig (CTX-009 - a DLL4 x VEGF-A bispecific...

Massachusetts-Based Biotech Soars On Analyst Coverage And Bullish Price Targer

Another healthcare stock came across our desk during the mid-week session after it was announced that Piper Sandler initiated coverage on the...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Compass Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference

BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage...

Another Day, Another Biotech Stealing The Show

A biotech company based out of Boston turned heads on Wednesday after the company announced the advancement of anew drug candidate as well as...

Form 8-K - Current report

Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate

Top-line Phase 2/3 data readout for CTX-009, now named tovecimig (a DLL4 x VEGF-A bispecific), in patients with...

Form 4 - Statement of changes in beneficial ownership of securities